Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?

iShares U.S. Pharmaceuticals ETF (IHE) is presented as the preferred 2026 healthcare ETF after delivering a 50.0% one-year return versus 29.0% for Invesco S&P 500 Equal Weight Health Care ETF (RSPH), with a lower 0.37% expense ratio and higher 1.4% dividend yield. IHE generated 19.9% and 11.9% annualized returns over three and five years, respectively, versus RSPH's 9.6% and 5.2%, while posting a smaller five-year maximum drawdown of 16% versus 22%. The tradeoff is concentration: Johnson & Johnson and Eli Lilly alone account for 43% of IHE assets, whereas RSPH's equal-weight construction keeps its top 10 holdings near 23% of the portfolio.

Analysis

The relevant exposure is not “pharma versus healthcare,” but mega-cap obesity/oncology franchise duration versus an equal-weight basket with materially more provider, tools, CRO and biotech sensitivity. IHE’s concentration makes it effectively a LLY/JNJ factor vehicle: continued prescription-volume and pricing resilience can support earnings revisions, but any deceleration in LLY’s incretin growth or a policy-driven drug-pricing headline would transmit directly to the ETF. RSPH is the better expression of a broadening healthcare recovery, particularly if rate stability re-rates mid-cap life-science tools and idiosyncratically depressed biotech holdings.

IHE’s recent relative strength likely leaves its downside asymmetry worse over the next 1-3 months than trailing volatility implies. A modest multiple de-rating in LLY, combined with patent-cliff concerns at MRK and less defensive demand for JNJ, can create a concentrated drawdown even without deterioration in healthcare fundamentals. Conversely, RSPH’s equal-weight structure should benefit more from a falling-rate or risk-on rotation because smaller constituents have greater duration sensitivity and more room for estimate recovery.

The underappreciated structural issue is that equal-weight healthcare is not a clean defensive substitute: it embeds higher operational leverage to biotech funding conditions, clinical-trial activity and hospital/lab capital budgets. CRL and VEEV-type exposures improve if biopharma R&D budgets normalize over 6-18 months, while MRNA remains a high-volatility source of both upside and rebalance drag. The near-term relative trade should therefore be driven by LLY earnings/reimbursement signals and the direction of real yields, rather than by aggregate healthcare sentiment.

Key Decisions for Investors

• Use a 1-3 month relative-value position: long RSPH / short IHE in equal dollar terms after a further IHE relative-strength extension. Thesis is mean reversion from concentrated mega-pharma leadership into mid-cap healthcare breadth; target 8-12% relative return, with a 5% relative stop if LLY raises forward demand or margin guidance.
• For existing IHE exposure, hedge single-name concentration rather than adding broad healthcare beta: buy LLY downside puts spanning the next earnings date or reduce IHE if LLY trades materially ahead of consensus revenue revisions. A reimbursement expansion or sustained upward prescription revisions would invalidate the hedge.
• Maintain a 6-18 month watchlist long in CRL and VEEV rather than treating RSPH as a pure defensive allocation. Initiate only on evidence of improving book-to-bill, R&D-budget commentary, or accelerating remaining-performance-obligation growth; absent those data, the recovery thesis is unconfirmed.
• Avoid using MRNA as a core RSPH proxy. Its clinical/regulatory outcomes can dominate short-horizon volatility; consider it only as an event-driven position with defined downside, not as a broad healthcare rotation expression.